What is Global NASH Therapeutic Drugs Market?
The Global NASH Therapeutic Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the development and distribution of therapeutic drugs for the treatment of Non-Alcoholic Steatohepatitis (NASH). NASH is a type of fatty liver disease that is not caused by alcohol consumption, but rather by a variety of factors such as obesity, diabetes, and high cholesterol. This condition can lead to serious health complications like cirrhosis and liver cancer if left untreated. The Global NASH Therapeutic Drugs Market is dedicated to providing effective treatment options for this disease, with a range of drugs that are designed to target and alleviate the symptoms of NASH. These drugs are developed through rigorous research and testing, ensuring their safety and efficacy for patients worldwide. The market is driven by the increasing prevalence of NASH and the growing need for effective treatments.
Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc in the Global NASH Therapeutic Drugs Market:
The Global NASH Therapeutic Drugs Market includes a variety of therapeutic drugs, such as Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, and Cenicriviroc. Vitamin E and Pioglitazone are antioxidants that help to reduce inflammation and prevent damage to the liver. Ocaliva is a drug that works by reducing the amount of bile in the liver, helping to slow the progression of NASH. Elafibranor is a dual PPARα/δ agonist that helps to improve insulin sensitivity and reduce inflammation. Selonsertib is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor that helps to reduce liver fibrosis. Cenicriviroc is a CCR2/5 antagonist that helps to reduce inflammation and fibrosis in the liver. These drugs are all part of the Global NASH Therapeutic Drugs Market, providing a range of treatment options for patients with NASH.
Hospital Pharmacy, Online Provider, Retail Pharmacy in the Global NASH Therapeutic Drugs Market:
The Global NASH Therapeutic Drugs Market is utilized in various areas such as Hospital Pharmacy, Online Provider, and Retail Pharmacy. Hospital pharmacies are a primary distribution channel for these drugs, as they provide direct access to patients in need of treatment. Online providers offer a convenient platform for patients to purchase their medications from the comfort of their own homes. Retail pharmacies also play a crucial role in the distribution of these drugs, as they provide easy access for patients in various locations. Each of these distribution channels plays a crucial role in ensuring that patients have access to the necessary treatment for NASH.
Global NASH Therapeutic Drugs Market Outlook:
Looking at the market outlook, the global pharmaceutical market, which includes the Global NASH Therapeutic Drugs Market, is projected to reach a value of 1475 billion USD in 2022. This represents a Compound Annual Growth Rate (CAGR) of 5% over the next six years. In contrast, the chemical drug market is expected to grow from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. This data indicates a steady growth in the pharmaceutical industry, with the Global NASH Therapeutic Drugs Market playing a significant role in this expansion. The increasing prevalence of NASH and the growing need for effective treatments are key factors driving this growth.
| Report Metric | Details |
| Report Name | NASH Therapeutic Drugs Market |
| CAGR | 5% |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Allergan Plc (Tobira), Bristol Myers Squibb, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Zydus Cadila |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
